ACLXArcellx, Inc.

$7B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M-89.2% YoY

Gross Profit

$12,9990.8% margin

Operating Income

-$64M-3850.2% margin

Net Income

-$58M-3513.4% margin

EPS (Diluted)

$-1.00

QoQ Revenue Growth

-66.6%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$59M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$604M

Total Liabilities

$202M

Stockholders' Equity

$402M

Cash & Equivalents

$80M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$15M	-89.2%
Gross Profit	$12,999	$15M	-99.9%
Operating Income	-$64M	-$53M	-19.8%
Net Income	-$58M	-$47M	-23.4%

ACLX Q4 2025 Earnings — Arcellx, Inc. Revenue & Financial Results | Market Cap Arena